Comprehensive treatment of recurrent and metastatic nasopharyngeal carcinoma: advances and future directions

被引：5

作者：

Fan, Ming ^{[1
,2
]}

Liu, Dengqun ^{[2
,3
]}

Zhu, Guiquan ^{[4
]}

Ren, Yazhou ^{[5
]}

Feng, Mei ^{[1
,2
,6
]}

机构：

[1] Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Dept Radiat Oncol, Chengdu, Peoples R China

[2] Univ Elect Sci & Technol China, Sch Med, Chengdu, Peoples R China

[3] Sichuan Canc Hosp & Inst, Sichuan Canc Prevent Ctr, Dept Radiat Biol, Radiat Oncol Key Lab Sichuan Prov, Chengdu, Peoples R China

[4] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis,Dept Head & Neck Oncol Surg, Chengdu, Peoples R China

[5] Univ Elect Sci & Technol China, Sch Comp Sci & Engn, Chengdu, Peoples R China

[6] Third Peoples Hosp Sichuan Prov, 121 Jinglong Rd, Chengdu 610100, Sichuan, Peoples R China

来源：

PRECISION RADIATION ONCOLOGY | 2022年 / 6卷 / 04期

关键词：

intensity-modulated radiotherapy; multimodality imaging techniques; nasopharyngeal carcinoma; programmed cell death 1 inhibitors; proton therapy; PREVIOUSLY TREATED RECURRENT; ANTITUMOR-ACTIVITY; OPEN-LABEL; MULTICENTER; CISPLATIN; THERAPY; SAFETY; CAMRELIZUMAB; RADIOTHERAPY; GEMCITABINE;

D O I：

10.1002/pro6.1181

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The standard of care for patients with recurrent and metastatic nasopharyngeal carcinoma remains unclear. There is an urgent need to identify effective and low-toxicity treatment methods for such patients. The integration of current evidence to form an optimal treatment modality for recurrent and/or metastatic nasopharyngeal is worth exploring. In recent years, several outstanding clinical trials have emerged for the comprehensive treatment of recurrent and/or metastatic nasopharyngeal carcinoma . New evidence has been added for the local treatment of patients with metastasis. Endoscopic surgery, radiomics, and other technologies help achieve precise local treatment. Novel immunotherapeutic drugs have been approved for the treatment of patients with metastasis in China. The combination of immunotherapy, chemotherapy, and targeted therapy is promising and requires confirmation. Future studies will continue to focus on individualization and precision medicine.

引用

页码：328 / 334

页数：7

共 25 条

[1]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[2]

Chen SY., 2022, J Clin Oncol, V40, P40

[3] Nasopharyngeal carcinoma [J].

Chen, Yu-Pei ;

Chan, Anthony T. C. ;

Quynh-Thu Le ;

Blanchard, Pierre ;

Sun, Ying ;

Ma, Jun .

LANCET, 2019, 394 (10192) :64-80

[4] Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis [J].

Du, Chengrun ;

Ni, Mengshan ;

Jiang, Jianyun ;

Kong, Fangfang ;

Zhai, Ruiping ;

Lv, Yingchen ;

Hu, Chaosu ;

Ying, Hongmei .

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2022, 279 (08) :3947-3956

[5] Dynamic Three-Dimensional ADC Changes of Parotid Glands During Radiotherapy Predict the Salivary Secretary Function in Patients With Head and Neck Squamous Carcinoma [J].

Feng, Mei ;

Yin, Qingping ;

Ren, Jing ;

Wu, Fei ;

Lan, Mei ;

Wang, He ;

Wang, Min ;

Li, Lu ;

Chen, Xiaojian ;

Lang, Jinyi .

FRONTIERS IN ONCOLOGY, 2021, 11

[6] Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study [J].

Hong, Shaodong ;

Zhang, Yaxiong ;

Yu, Gengsheng ;

Peng, Peijian ;

Peng, Jiewen ;

Jia, Jun ;

Wu, Xuan ;

Huang, Yan ;

Yang, Yunpeng ;

Lin, Qing ;

Xi, Xuping ;

Xu, Mingjun ;

Chen, Dongping ;

Lu, Xiaojun ;

Wang, Rensheng ;

Cao, Xiaolong ;

Chen, Xiaozhong ;

Lin, Zhixiong ;

Xiong, Jianping ;

Lin, Qin ;

Xie, Conghua ;

Li, Zhihua ;

Pan, Jianji ;

Li, Jingao ;

Wu, Shixiu ;

Lian, Yingni ;

Yang, Quanlie ;

Zhao, Chong ;

Fang, Wenfeng ;

Zhang, Li .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (29) :3273-+

[7] Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study [J].

Hsu, Chiun ;

Lee, Se-Hoon ;

Ejadi, Samuel ;

Even, Caroline ;

Cohen, Roger B. ;

Le Tourneau, Christophe ;

Mehnert, Janice M. ;

Algazi, Alain ;

van Brummelen, Emilie M. J. ;

Saraf, Sanatan ;

Thanigaimani, Pradeep ;

Cheng, Jonathan D. ;

Hansen, Aaron R. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) :4050-+

[8] Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial [J].

Hua, Yijun ;

You, Rui ;

Wang, Zhiqiang ;

Huang, Peiyu ;

Lin, Mei ;

Ouyang, Yanfeng ;

Xie, Yulong ;

Zou, Xiong ;

Liu, Youping ;

Duan, Chongyang ;

Liu, Yonglong ;

Gu, Chenmei ;

Liu, Rongzeng ;

Yang, Qi ;

Jiang, Rou ;

Zhang, Mengxia ;

Ding, Xi ;

Chen, Siyuan ;

Lin, Chao ;

Sun, Rui ;

Chen, Mingyuan .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)

[9] A Systematic Review of Proton Therapy for the Management of Nasopharyngeal Cancer [J].

Lee, Anna ;

Kitpanit, Sarin ;

Chilov, Marina ;

Langendijk, Johannes A. ;

Lu, Jiade ;

Lee, Nancy Y. .

INTERNATIONAL JOURNAL OF PARTICLE THERAPY, 2021, 8 (01) :119-130

[10]

Li Zhang., 2022, J Clin Oncol, V40, P40

← 1 2 3 →